Humacyte (NASDAQ:HUMA) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report released on Tuesday,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock.

A number of other brokerages have also recently weighed in on HUMA. Benchmark reiterated a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $11.71.

Humacyte Trading Up 1.1%

Humacyte stock opened at $1.89 on Tuesday. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.97. The stock has a market cap of $293.17 million, a P/E ratio of -1.41 and a beta of 1.64. The company has a 50-day moving average price of $1.84 and a 200 day moving average price of $3.51.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million. As a group, analysts forecast that Humacyte will post -1.27 EPS for the current year.

Insider Activity

In other Humacyte news, Director Kathleen Sebelius acquired 50,000 shares of the stock in a transaction dated Tuesday, April 8th. The stock was acquired at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the purchase, the director now owns 91,207 shares in the company, valued at $120,393.24. This trade represents a 121.34% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Dale A. Sander acquired 20,000 shares of the stock in a transaction dated Thursday, April 10th. The stock was acquired at an average cost of $1.53 per share, with a total value of $30,600.00. Following the purchase, the chief financial officer now owns 40,600 shares of the company’s stock, valued at approximately $62,118. This trade represents a 97.09% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 83,993 shares of company stock valued at $118,224. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HUMA. Heights Capital Management Inc. purchased a new position in shares of Humacyte in the first quarter valued at approximately $6,863,000. RA Capital Management L.P. purchased a new position in Humacyte in the first quarter worth approximately $5,648,000. Woodline Partners LP grew its holdings in Humacyte by 235.7% during the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after acquiring an additional 2,000,268 shares in the last quarter. Monashee Investment Management LLC acquired a new position in Humacyte during the 1st quarter worth approximately $3,410,000. Finally, CenterBook Partners LP acquired a new position in Humacyte during the 4th quarter worth approximately $6,463,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.